BiomX Inc.
PHGENYSE
$0.20
↓ -3.4%Jul 17 close · end-of-day
Price
1Y↓ -97.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
0.0
P/S
—
P/B
—
EV/EBITDA
—
PEG
0.0
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$47.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
5412.0%
ROIC
—
Debt / Equity
—
Net Cash
$1.2M
Return 1Y
-97.4%
Company profile
BiomX Inc. develops products using natural and engineered phage technologies to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC) The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.Aureus), a bacteria associated
- CEO
- Jonathan E. Solomon
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 120
- Website
- biomx.com
Earnings
PHGE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS$7.38↑ +17.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$30.3M | -$35.5M | -$27.2M | -$25.3M | -$44.5M | -$41.5M |
| Net income | -$30.1M | -$36.2M | -$28.3M | -$26.2M | -$17.7M | -$36.2M |
| Diluted EPS | — | $1.39 | $0.95 | $5.10 | $58.31 | $22.19 |
| Operating cash flow | -$24.4M | -$27.6M | -$29.1M | -$21.3M | -$37.0M | -$26.4M |
| Free cash flow | -$25.5M | -$31.3M | -$29.2M | -$21.3M | -$37.0M | -$26.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.7M | -$11.3M | -$16.7M | -$7.8M | -$7.4M | -$8.5M | -$17.7M | -$1.3M |
| Net income | $4.5M | $9.6M | -$14.5M | -$7.7M | -$6.0M | -$9.2M | -$13.3M | -$19.1M |
| Diluted EPS | $0.69 | -$0.31 | $55.15 | $6.27 | $0.19 | $0.29 | $15.44 | $7.38 |
| Operating cash flow | -$11.2M | -$8.1M | -$6.3M | -$8.7M | -$6.1M | -$7.2M | -$4.4M | -$5.4M |
| Free cash flow | — | -$8.1M | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-17 | Yeganeh Reuven | Sale | 530,000 | $5.00 | $2.6M | filing |
| 2026-03-17 | Yeganeh Reuven | C | 530,000 | $2.00 | $1.1M | filing |
| 2026-03-16 | Yeganeh Reuven | Sale | 450,000 | $5.00 | $2.3M | filing |
| 2026-03-16 | Yeganeh Reuven | C | 450,000 | $2.00 | $900,000.00 | filing |
| 2026-03-13 | Yeganeh Reuven | Sale | 370,000 | $5.00 | $1.9M | filing |
| 2026-03-13 | Yeganeh Reuven | C | 370,000 | $2.00 | $740,000.00 | filing |
| 2026-03-12 | Yeganeh Reuven | Sale | 300,000 | $5.00 | $1.5M | filing |
| 2026-03-11 | Yeganeh Reuven | C | 300,000 | $2.00 | $600,000.00 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.